{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:35:05Z","timestamp":1786649705425,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To study the refractive profile of children after they received intravitreal injection of bevacizumab for retinopathy of prematurity (ROP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was conducted at a tertiary eye care hospital in South India. ROP patients of more than 1 year of age, presenting to the Pediatric Ophthalmology Clinic and Retina Clinic and having history of treatment for type I ROP with intravitreal bevacizumab (IVB) or intravitreal bevacizumab and laser photocoagulation were included in the study. Cycloplegic refraction was done, and the refractive status was evaluated. The refractive status of age-matched, full-term children with uneventful perinatal and neonatal history was also recorded and compared to the study group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 134 eyes of 67 study subjects, the major refractive error was myopia in 93 eyes (69.4%; spherical equivalent [SE] = \u22122.89 \u00b1 3.1, range = \u221211.5 to \u22120.5 D). There were 75 eyes (56%) with low-to-moderate myopia; high myopia was seen in 13.4%, emmetropia in 18.7%, and hypermetropia in 11.9% of eyes. The majority of them (87%) had with-the-rule (WTR) astigmatism. In 134 eyes, the SE was \u22121.78 \u00b1 3.2 (range = \u221211.5 to 4 D); the SE of the 75 eyes with low-to-moderate myopia was \u22121.53 \u00b1 1.2 (range = \u22120.50 to \u22125 D). In the control group, the majority had emmetropia (91.8%). There was no significant association between the age at which IVB had been injected and the development of refractive errors (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.078). The prevalence of low-to-moderate myopia was more than high myopia in patients with zone I and zone II ROP before treatment (60.0% and 54.5%, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Myopia was the major refractive error seen in post-IVB pediatric patients. WTR astigmatism was more commonly seen. The age at which IVB injection had been given had no effect on the development of refractive errors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1209_22","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T09:04:55Z","timestamp":1686733495000},"page":"2561-2568","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity"],"prefix":"10.4103","volume":"71","author":[{"given":"Neelam","family":"Pawar","sequence":"first","affiliation":[{"name":"Pediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Somyashree","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Meenakshi","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Mohideen","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Sithiq","family":"Uduman","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development:Implications for screening programs","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/EB.S94436","article-title":"Retinopathy of prematurity blindness worldwide:Phenotypes in the third epidemic","volume":"8","author":"Quinn","year":"2016","journal-title":"Eye Brain"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/bjophthalmol-2012-302801","article-title":"Comparison of profile of retinopathy of prematurity in semiurban\/rural and urban NICUs in Karnataka, India","volume":"97","author":"Murthy","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study:Findings to 3 years of age","volume":"1156","author":"Quinn","year":"2008","journal-title":"Ophthalmology"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4103\/ijo.IJO_783_17","article-title":"Retinopathy of prematurity:An emerging and evolving challenge","volume":"65","author":"Dogra","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5409\/wjcp.v5.i1.35","article-title":"Retinopathy of prematurity:Past, present and future","volume":"5","author":"Shah","year":"2016","journal-title":"World J Clin Pediatr"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1167\/iovs.10-5234","article-title":"Long-term evaluation of refractive status and optical components in eyes of children born prematurely","volume":"51","author":"Chen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity:Refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity:2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye (Lond)"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000439182","article-title":"Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy","volume":"234","author":"Kuo","year":"2015","journal-title":"Ophthalmologica"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"e0225643","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents:A meta-analysis and systematic review","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"2","author":"Roohipoor","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment:A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"R18-20251006","first-page":"CD00973","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20251006","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"R20-20251006","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity:A 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R21-20251006","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R22-20251006","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity:A multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"R23-20251006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.10.4.14","article-title":"Longitudinal development of refractive error in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity","volume":"10","author":"Simmons","year":"2021","journal-title":"Trans Vis SciTechnol"},{"key":"R24-20251006","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/09273972.2016.1159232","article-title":"Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Gunay","year":"2016","journal-title":"Strabismus"},{"key":"R25-20251006","doi-asserted-by":"crossref","first-page":"e042384","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity:A meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"key":"R26-20251006","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"key":"R27-20251006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","article-title":"Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation","volume":"104","author":"Chen","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R28-20251006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaapos.2016.09.013","article-title":"Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era:A literature review","volume":"20","author":"Abri Aghdam","year":"2016","journal-title":"J AAPOS"},{"key":"R29-20251006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity:Efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"R30-20251006","doi-asserted-by":"crossref","first-page":"4565216","DOI":"10.1155\/2018\/4565216","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab:A clinical study of correction at three years of age","volume":"2018","author":"Chen","year":"2018","journal-title":"J Ophthalmol"},{"key":"R31-20251006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ajo.2022.03.020","article-title":"Longitudinal change of refractive error in retinopathy of prematurity treated with intravitreal bevacizumab or laser photocoagulation","volume":"240","author":"Wiecek","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R32-20251006","first-page":"1639","volume":"101","year":"2003","journal-title":"Ophthalmology"},{"key":"R33-20251006","first-page":"88","article-title":"Outcomes After Laser Versus Combined Laser And Bevacizumab Treatment For Type 1 Retinopathy Of Prematurity In Zone I Retina","volume":"37","author":"Je","year":"2017"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1209_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:18Z","timestamp":1786647438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1209_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1209_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-05-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}